Skip to main content
. Author manuscript; available in PMC: 2018 Oct 25.
Published in final edited form as: J Am Chem Soc. 2017 Oct 16;139(42):15074–15087. doi: 10.1021/jacs.7b07906

Figure 5.

Figure 5

SPR analysis of the binding between FcγRIIIA-V158 and various glycoforms of rituximab. The antibodies were immobilized on a protein A chip and and the Fc receptor was run as analytes at 2X serial dilutions starting at 2 μM. A) binding with non-fucosylated sialyl complex type rituximab (28); B) binding with core-fucosylated sialyl complex type rituximab (30); C) binding with GlcNAc-rituximab (27); D) binding with Fucα1,6GlcNAc-rituximab (29).